NEETPGAI
BlogComparePricing
Log inStart Free
NEETPGAI

AI-powered NEET PG preparation platform. Master all 19 subjects with adaptive MCQs, AI tutoring, and spaced repetition.

Product

  • Subjects
  • Previous Year Questions
  • Compare
  • Pricing
  • Blog

Features

  • Adaptive MCQ Practice
  • AI Tutor
  • Mock Tests
  • Spaced Repetition

Resources

  • Blog
  • Study Guides
  • NEET PG Updates
  • Help Center

Legal

  • Privacy Policy
  • Terms of Service

Stay updated

© 2026 NEETPGAI. All rights reserved.
    Subjects/Campylobacter and Helicobacter pylori
    Campylobacter and Helicobacter pylori
    hard

    A 42-year-old man from Delhi with a 6-month history of epigastric pain, early satiety, and bloating undergoes upper endoscopy. Gastric antral biopsies are obtained. Histology shows chronic active gastritis with intestinal metaplasia. Rapid urease test on the biopsy is positive. What is the most likely diagnosis, and which medication should be AVOIDED in the triple therapy regimen due to high resistance in India?

    A. Campylobacter jejuni gastritis; Avoid Clarithromycin due to high resistance
    B. Helicobacter pylori infection; Avoid Omeprazole due to high resistance
    C. Helicobacter pylori infection; Avoid Amoxicillin due to high resistance (>50% in India)
    D. Helicobacter pylori infection; Avoid Metronidazole due to high resistance (>40% in India)

    Explanation

    ## Diagnosis: Helicobacter pylori Chronic Gastritis ### Clinical & Histological Features **Key Point:** Chronic epigastric pain with early satiety and bloating in a 42-year-old, combined with histological chronic active gastritis and intestinal metaplasia, is classic for H. pylori–induced chronic gastritis. **High-Yield:** The **rapid urease test (RUT)** is positive — H. pylori produces urease, which cleaves urea to ammonia and CO₂, raising local pH and allowing bacterial survival in the acidic stomach. ### Resistance Patterns in India | Antibiotic | Resistance Rate in India | Clinical Impact | |---|---|---| | **Metronidazole** | >40% | High resistance; avoid in empiric regimens | | **Clarithromycin** | 20–30% | Moderate resistance; still used but declining efficacy | | **Amoxicillin** | <5% | Very low resistance; preferred | | **Tetracycline** | <5% | Very low resistance; used in quadruple therapy | **Clinical Pearl:** Metronidazole resistance in India is driven by prior use in anaerobic infections and giardiasis. Current Indian guidelines recommend **avoiding metronidazole** in first-line H. pylori eradication regimens. ### Recommended Regimens (India) 1. **Bismuth-based quadruple therapy** (preferred in high-resistance areas): - PPI (Omeprazole 20 mg BD) + Bismuth subsalicylate + Tetracycline + Metronidazole (10–14 days) - OR: PPI + Bismuth + Tetracycline + Clarithromycin 2. **Alternative triple therapy** (if bismuth unavailable): - PPI + Amoxicillin + Clarithromycin (10–14 days) - Success rate ~85–90% if clarithromycin-susceptible **Warning:** Do NOT use metronidazole as first-line due to high resistance. Amoxicillin should be retained because of its excellent susceptibility. ### Why Rapid Urease Test is Diagnostic - H. pylori produces urease constitutively - RUT turns colour within 15–60 minutes if H. pylori is present - Sensitivity ~95%, Specificity ~98% [cite:Park 26e Ch 19; Harrison 21e Ch 155]

    Practice similar questions

    Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.

    Start Practicing Free